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Experimental Study of Clinafloxacin Alone and in
Combination in the Treatment of Ciprofloxacin-Susceptible
and -Resistant Pneumococcal Meningitis
A. DOMENECH, C. CABELLOS, S. RIBES, F. TUBAU, P.F. VILADRICH, J. LIÑARES, and F. GUDIOL
ABSTRACT
The increasing incidence of ciprofloxacin resistance in Streptococcus pneumoniae may limit the efficacy of the
new quinolones in difficult-to-treat infections such as meningitis. The aim of the present study was to deter-
mine the efficacy of clinafloxacin alone and in combination with teicoplanin and rifampin in the therapy of
ciprofloxacin-susceptible and ciprofloxacin-resistant pneumococcal meningitis in rabbits. When used against
a penicillin-resistant ciprofloxacin-susceptible strain (Clinafloxacin MIC 0.12 mg/ml), clinafloxacin at a dose
of 20 mg/kg per day b.i.d. decreased bacterial concentration by 25.10 log cfu/ml at 24 hr. Combinations did
not improve activity. The same clinafloxacin schedule against a penicillin- and ciprofloxacin-resistant strain
(Clinafloxacin MIC 0.5 mg/ml) was totally ineffective. Our data suggest that a moderate decrease in quinolone
susceptibility, as indicated by the detection of any degree of ciprofloxacin resistance, may render these an-
tibiotics unsuitable for the management of pneumococcal meningitis.
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INTRODUCTION
THE WORLDWIDE INCREASE in penicillin- and cephalosporin-resistant pneumococci has led to changes in the therapy
of pneumococcal infections. The combination of high doses
of cefotaxime and vancomycin is recommended by most au-
thorities for pneumococcal meningitis caused by resistant
strains, as well as for initial empirical therapy. In patients in-
fected by hypothetical strains with very high cephalosporin
resistance and in those with penicillin allergy, the use of non-
b-lactam antibiotics may be warranted.7,12,23–25 Glycopep-
tides, rifampin, and the new quinolones are among potentially
effective antibiotics in this setting. Monotherapy with sys-
temic vancomycin in adults has been associated with clinical
and bacteriological failures, better explained by the erratic and
borderline vancomycin cerebrospinal fluid (CSF) levels,
which fall when dexamethasone is administered concomi-
tantly.26 Teicoplanin alone as well as the combination of ri-
fampin and vancomycin, with and without dexamethasone,
have all been effective in the rabbit model of pneumococcal
meningitis, but clinical experience is lacking.6,13
Quinolones enter the CSF better than other classes of an-
timicrobial agents and are rapidly bactericidal for susceptible
organisms in a highly concentration-dependent way.19 Cipro-
floxacin has excellent activity against Gram-negative organisms
and has been successfully used for the treatment of Gram-neg-
ative bacillary meningitis in animal models and patients, but its
activity is insufficient for treating meningitis due to Gram-pos-
itive organisms.
In recent years, new quinolones with enhanced activity
against S. pneumoniae (including clinafloxacin, trovafloxacin,
moxifloxacin, grepafloxacin, gatifloxacin, and gemifloxacin)
have proven to be potentially useful for the treatment of ex-
perimental meningitis caused by penicillin- and cephalosporin-
resistant pneumococcal strains.2,8,9,11,15,17,18,21 However, the
increasing incidence of ciprofloxacin resistance in S. pneumo-
niae may reduce the efficacy of these new quinolones for treat-
ing meningitis, because cross-resistance is likely to occur. In
fact, although their activity against pneumococcal strains with
high ciprofloxacin MICs remains good, susceptibility to all
drugs in the class is decreased to some extent.3,10
To date, few studies have assessed the influence of this re-
sistance on the therapeutic efficacy of the new quinolones in
experimental pneumococcal meningitis. The aim of the present
study was to determine the efficacy of clinafloxacin, alone 
and in combination with teicoplanin and rifampin, to treat
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ciprofloxacin-susceptible (CS) and ciprofloxacin-resistant (CR)
pneumococcal meningitis in rabbits.
MATERIALS AND METHODS
Bacterial strains
Two S. pneumoniae strains were used. Strain 2349, belong-
ing to serotype 23 F, was recovered from a patient with pneu-
mococcal meningitis and strain 4371, belonging to serotype 9
V, was recovered from a patient with chronic bronchitis. MICs
were determined by microdilution method in cation-supple-
mented Mueller-Hinton broth with 5% whole defribinated horse
blood and the appropriate concentration of antibiotic. The wells
of microdilution plates were inoculated to a volume of 100 ml
with an inoculum containing 1 million cfu/ml. MICs of strain
2349 were as follows: penicillin, 4 mg/ml; ceftriaxone/cefo-
taxime, 2 mg/ml; clinafloxacin, 0.12 mg/ml; ciprofloxacin, 2
mg/ml; teicoplanin, 0.03 mg/ml; rifampin, 0.06 mg/ml; van-
comycin, 0.25 mg/ml. MICs of strain 4371 were: penicillin, 2
mg/ml; ceftriaxone/cefotaxime, 1 mg/ml; clinafloxacin, 0.5
mg/ml; ciprofloxacin, .32 mg/ml; teicoplanin, 0.12 mg/ml; ri-
fampin, 0.03 mg/ml; vancomycin, 0.25 mg/ml. The CR strain
was previously examined within the quinolone-resistance-
determining regions, showing mutations in ParC (S79Y), ParE
(I460V), and GyrA (S81F). This strain also demonstrated an ef-
flux mechanism.10 The possibility of a change in MIC during
therapy was investigated by re-assessing MICs in the colonies
growing in CSF at 24 hr of therapy.
Inoculum preparation
Colonies from fresh overnight cultures on 5% blood agar
plates were resuspended and grown for 4–6 hr at 37°C in BHI
broth medium. Immediately before inoculation, cultures in BHI
were centrifuged and resuspended in sterile saline, adjusted to an
optical density of 0.5 McFarland (,108 cfu/ml), and then diluted
to the appropriate size. A final inoculum of 106 cfu/ml was used.
The inoculum size was confirmed by quantitative cultures.
Rabbit model of meningitis
The rabbit model of meningitis was based on an established
protocol.4 The study was approved by the Ethical Committee
for Animal Experiments at the University of Barcelona (Bell-
vitge Campus). Treatment groups were formed, each compris-
ing 8 rabbits, along with a control group, which was inoculated
but not treated. Two-kilogram female New Zealand white rab-
bits were anesthetized intramuscularly with 35 mg of ketamine
(Ketolar®, Parke-Davis, El Prat de Llobregat, Spain) and 5 mg
of xylazine (Rompun®, Bayer AG, Leverkusen, Germany) per
kg of body weight, and a dental acrylic helmet was affixed to
the calvarium. Twenty-four hours later, the animals were anes-
thetized again and placed in a stereotaxic frame. A spinal nee-
dle was introduced into the cisterna magna, 200 ml of CSF were
withdrawn, and 200 ml of a 106 cfu/ml inoculum of one of the
infecting strains were instilled. Eighteen hours later, the rabbits
were anesthetized again with urethane 1.75 g/kg, subcuta-
neously (s.c.) (Sigma Chemical Company, St. Louis MO) and
thiopental 5 mg/kg, intravenously (i.v.) (Penthotal® sodico, Ab-
bott Laboratories, Madrid, Spain), and a baseline CSF sample
was taken. In the experiments with the CS strain, at this point
(0 hr), an i.v. dose of either clinafloxacin (Parke-Davis, Ann Ar-
bor, MI) 10 mg/kg per day, 20 mg/kg per day in a single dose
or 20 mg/kg per day in two divided doses (b.i.d.), or a combi-
nation of clinafloxacin 20 mg/kg per day b.i.d. with teicoplanin
15 mg/kg per day (Targocid®, Hoechst-Marion-Roussell,
Barcelona, Spain) or rifampin 15 mg/kg per day (Rifaldin®,
Hoechst-Marion-Roussell, Barcelona, Spain) was administered.
Saline (Suero fisiológico Braun, Braun S.A. Rubí, Barcelona,
Spain) was given to the controls. Teicoplanin and rifampin were
administered every 24 hr. In the experiments with the CR strain,
only the last dose, 20 mg/kg per day b.i.d., was used alone and
in combination. Hydration was ensured with 20 ml of saline in-
jected s.c. three times throughout the experiment. Serial CSF
samples were taken at 2 (peak), 6, 24 (trough), and 26 (peak) hr
of treatment. CSF samples were used to perform direct 
and quantitative bacterial cultures and white blood cell (WBC)
counts, as well as to determine concentrations of lactic acid, to-
tal protein, and CSF clinafloxacin at trough and peak time points.
WBC counts were performed by optical microscopy (403)
with a Neubauer chamber after WBC had been lysed with Turk
solution (1:1, self-laboratory made). CSF lactic acid concen-
trations were determined by the Lactate PAP technique (Bio-
mérieux SA, 69280 Marcy l’Etoile, France) and read by spec-
trophotometer (505 nm). CSF total protein concentrations were
determined by the Bio-Rad Protein Assay technique (BioRad
Laboratories, München, Germany) using bovine serum albumin
as the standard protein, and also read by spectrophotometer (595
nm). Serial 10-fold dilution cultures of CSF were made to de-
termine bacterial counts at each time point (the detection limit
by this method was 102 cfu/ml; a value of 1.9 log cfu/ml was
assigned to the first sterile culture and a value of 0 to the sub-
sequent ones). To avoid carryover antimicrobial agent interfer-
ence, the sample was placed onto the plate in a single streak
down the center and allowed to be absorbed into the agar un-
til the plate surface appeared dry; the inoculum was then spread
over the plate. Plates were incubated overnight at 37°C.
CSF clinafloxacin levels were measured by the disk diffu-
sion bioassay method.1 The assay organism was Escherichia
coli ATCC 25922, and the assay medium was DIFCO antibi-
otic medium No. 1. The minimal detectable concentration was
0.25 mg/ml. Teicoplanin and rifampin controls were performed
in E. coli plates to ensure that no teicoplanin or rifampin ac-
tivity would be found when assaying clinafloxacin-teicoplanin
and clinafloxacin-rifampin samples. The area under the con-
centration-time curve (AUC) was calculated by a computer-as-
sisted method according to the trapezoidal rule.
Therapeutic failure was defined as an increase in bacterial
concentration of at least 1 log cfu/ml compared with a previ-
ous count. A therapy was considered bactericidal when it
achieved a reduction of 3 log cfu/ml. A synergistic effect of
one combination was defined as a decrease $2 log cfu/ml com-
pared with the most active antibiotic alone.
Statistical analysis
Student’s t-test and analysis of variance (ANOVA) were used
to compare continuous normally distributed variables. Non-
parametric data were analyzed using the Mann-Whitney test.
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Comparisons between treatment groups were performed by
ANOVA. Student’s t or Mann-Whitney tests were used for 
comparisons between CS and CR strains.
RESULTS
Bacterial concentration
With the CS strain (2349), use of clinafloxacin at 10 mg/kg
per day and 20 mg/kg per day (in a single dose) achieved an
initial reduction at 6 hr. in mean log cfu/ml of 24.56 6 0.62
and 24.89 6 1.5, respectively. Both were bactericidal at this
point but presented regrowth at 24 hr, and the final reduction
at 24 hr in mean log cfu/ml was 22.30 6 1.94 and 23.83
6 2.97.
Clinafloxacin at 20 mg/kg per day bid decreased bacterial
concentration by more than 4 log cfu/ml at 2 hr and at 24 hr
the reduction in mean log cfu/ml was 25.10 6 1.30. However,
there was a regrowth in 1 of 7 animals at this time point.
Combined therapy of clinafloxacin 20 mg/kg per day bid plus
teicoplanin 15 mg/kg per day decreased bacterial counts in more
than 2 log cfu/ml at 2 hr. Mean reduction at 24 hr in log cfu/ml
was 24.09 6 1.26. At 24 hr, 6 of 7 animals had CSF cultures
with bacterial counts below the level of detection. Combination
with rifampin 15 mg/kg per day achieved a slight reduction of
1.3 log cfu/ml at 2 hr, but at 24 hr 100% of animals had cul-
tures below the level of detection with reduction in mean log
cfu/ml of 22.95 6 0.91. Comparisons between bacterial counts
of different regimens and controls at several time points are
shown in Fig. 1.
With the CR strain (4371), clinafloxacin at 20 mg/kg per day
bid did not decrease bacterial titers at any time point. Mean log
cfu/ml increased by 1.50 6 2.49 at 24 hr. Mean log cfu/ml in
control animals increased by 0.99 6 2.10 at 24 hr. Therapy us-
ing clinafloxacin 20 mg/kg per day b.i.d. plus teicoplanin 15
mg/kg per day decreased bacterial counts by 2 log cfu/ml at 2
hr and at 24 hr mean log cfu/ml decreased by 22.60 6 0.26.
At 26 hr 100% of animals had cultures below the level of de-
tection. Combined therapy with rifampin 15 mg/kg per day
showed a slight reduction in bacterial concentration at 2 hr, and
at 24 hr, 100% of CSF cultures were below the level of detec-
tion with a mean reduction of log cfu/ml 22.38 6 1.14.
Comparison between clinafloxacin-treated group, combina-
tion groups and control group are shown in Fig. 2. Colonies
growing in CSF at 24 hr had the same susceptibility as the ini-
tial strain.
Initial CSF bacterial concentrations at 0 hr (baseline) were
significantly lower in the CR strain than in the CS strain.
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FIG. 1. CSF bacterial counts (expressed as mean log cfu/ml) of rabbits with ciprofloxacin-susceptible pneumococcal meningi-
tis. Therapies: clinafloxacin, 20 mg/kg per day b.i.d. alone (CLI 20) and in combination with teicoplanin 15 mg/kg day (CLI 1
TEI) or rifampin 15 mg/kg per day (CLI 1 RIF). *Statistically significant differences were found at 24 hr between all therapeu-
tic groups and the control group (p , 0.05).
CSF clinafloxacin levels
Mean CSF clinafloxacin peak and trough levels and
AUC/MIC parameter of both strains are shown in Table 1. In
animals with CS pneumococcal meningitis, mean peak con-
centration of clinafloxacin was 0.56 6 0.28 mg/ml and mean
trough level was 0.28 mg/ml; both were above the MIC.
Animals infected with the CR strain achieved a mean peak
CSF level of clinafloxacin of 0.36 6 0.14 mg/ml, lower than
the mean peak reached with the CS strain. Mean trough con-
centration was below the level of detection for all samples in
this group. Both peak and trough levels were below the MIC.
Inflammatory activity
CSF inflammatory parameters of rabbits with CS and CR
pneumococcal meningitis are shown in Table 2. Statistically
significant differences between strains were observed for WBC
and lactic acid.
Therapeutic failures
With the CS strain, there were no therapeutic failures in the
clinafloxacin 20 mg/kg per day b.i.d., clinafloxacin plus te-
icoplanin and clinafloxacin plus rifampin groups. With the CR
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FIG. 2. CSF bacterial counts (expressed as mean log cfu/ml) of rabbits with ciprofloxacin-resistant pneumococcal meningitis.
Therapies: clinafloxacin 20 mg/kg per day b.i.d. alone (CLI 20) and in combination with teicoplanin 15 mg/kg per day (CLI 1
TEI) or rifampin 15 mg/kg per day (CLI 1 RIF). #Statistically significant differences were found at 24 hr between the CLI 1
TEI and CLI 1 RIF groups and the CLI 20 and control groups (p , 0.05).
TABLE 1. MEAN 6 SD (N) CSF PEAK AND TROUGH LEVELS OF CLINAFLOXACIN FOR BOTH STRAINS: CS 2349 AND CR 4371
CSF peak level CSF trough level
Strain (mg/ml) (mg/ml) AUC/MICa
CS 2349 0.56 6 0.28 (6) 0.28 6 0.00 (3) 81.67
CR 4371 0.36 6 0.14 (5) b 8.64
aMICs of clinafloxacin are 0.12 and 0.5 for CS and CR strains.
bBelow the detection limit (0.25 mg/ml).
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strain, there were 8 of 8 therapeutic failures when using cli-
nafloxacin alone at 20 mg/kg per day b.i.d. No therapeutic fail-
ures were found with combined therapies.
DISCUSSION
In this rabbit model of meningitis, clinafloxacin showed a
very good antimicrobial activity against the penicillin-resistant,
ciprofloxacin-susceptible pneumococcal strain 2349 (clina-
floxacin MIC 0.12 mg/ml). It was bactericidal at 2 hr. Although
there was a regrowth at 24 hr in 1 of 7 rabbits, no therapeutic
failures were observed. After performing dose-ranging studies,
dose regimen of 20 mg/kg per day administered every 12 hr ap-
peared to be the most effective in this model, achieving CSF
levels several times above the MIC over the entire treatment
period and an AUC/MIC of 81.67. These results are in accor-
dance with those obtained by Friedland et al.,7 using doses of
20 mg/kg per day every 5 hr against a pneumococcal strain with
a clinafloxacin MIC of 0.06 mg/ml, and by Shapiro et al.,20 us-
ing doses of 21 mg/kg against a pneumococcal strain with a cli-
nafloxacin MIC of 0.03 mg/ml in a meningitis mouse model.
In previous studies, we have shown that both teicoplanin and
rifampin have good activity against pneumococcal strain
2349.6,13 In this study, combined therapy with clinafloxacin and
teicoplanin or clinafloxacin and rifampin did not improve the
activity of clinafloxacin alone, since no additive or synergistic
effect was found.
The intensity of the inflammatory response induced by an-
tibiotics is thought to be an important prognostic factor of pneu-
mococcal meningitis. Highly bacteriolytic antibiotics (espe-
cially b-lactams) strongly increase the inflammatory response
in the subarachnoidal space because of the massive bacterial ly-
sis produced in early stages of therapy.22 However, in rabbits
treated with clinafloxacin we observed an improvement of the
inflammatory parameters at 24 hr in all cases. This feature, also
reported in other studies using quinolones,16 suggests that
quinolones have an advantage over betalactam antibiotics in the
clinical setting.
Against the penicillin-resistant, ciprofloxacin-resistant pneu-
mococcal strain 4371 (clinafloxacin MIC 0.5 mg/ml), therapy
with the same dose regimen of clinafloxacin (20 mg/kg per day
in two divided doses) was totally ineffective, as the increase in
bacterial counts was similar to that of the control group. In ad-
dition, all inflammatory parameters increased between 0 hr and
24 hr, as was the case in the control group. These results are in
agreement with the fact that mean CSF peak and trough cli-
nafloxacin levels were below the MIC of the strain, with
AUC/MIC values of 8.64. The efficacy observed in rabbits re-
ceiving combination therapy was attributable to the bacterici-
dal effect of both teicoplanin and rifampin shown in previous
studies. Although failures in CR experiments are clearly related
to the inadequacy of the pharmacodynamic parameters, it is sur-
prising that rabbits infected with the CR strain had lower CSF
clinafloxacin levels than those infected with the CS strain. We
also found significantly lower bacterial counts and lower lev-
els of inflammatory activity in these rabbits (the differences be-
ing statistically significant for WBC and lactic acid), both at 18
hr after inoculation (baseline). One might hypothesize that this
CR strain, which is distantly related to the wild pneumococcus,
induces a lower inflammatory response and lower levels of sub-
sequent blood–brain barrier disruption than the CS strain. How-
ever, this disruption is not as important for lipid-soluble drugs
like quinolones as for b-lactams. In any event, even with CSF
clinafloxacin levels similar to those obtained in CS experiments,
the pharmacodynamic parameters were suboptimal.
We did not record the emergence of resistance during ther-
apy: MICs of the colonies growing in CSF at 24 hr of therapy
were identical to those of the initial isolates. However, this was
unlikely to occur in our experiments because the original CS
strain had no mutations, while the CR strain already had three
(parC, parE, and GyrA). Resistance selection might occur more
easily among strains harboring one-step mutation, as has been
shown in patients with pneumococcal pneumonia; in this re-
gard, these new quinolones should be used with caution against
strains harboring one mutation, signaled by any decrease in
ciprofloxacin susceptibility, or in patients with recent quinolone
use.5,14
It seems reasonable that the findings observed with cli-
nafloxacin, which has been withdrawn from last phase clinical
trials, may be generalized to all quinolones. In conclusion, cli-
nafloxacin at doses of 20 mg/kg per day b.i.d. was very effec-
tive for the therapy of penicillin-resistant, ciprofloxacin-
susceptible pneumococcal meningitis in the rabbit model. Com-
binations with teicoplanin and with rifampin did not improve
activity. The same clinafloxacin schedule was totally ineffec-
tive against a penicillin-resistant, ciprofloxacin-resistant pneu-
mococcal strain. A moderate decrease in quinolone suscepti-
bility, as indicated by the detection of any degree of
ciprofloxacin resistance, may render these antibiotics unsuit-
able for the management of pneumococcal meningitis.
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